ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1545

Covid-19 Vaccines: A Review on Technology, Safety and Global Impact

Dr. Ashwini Jadhav[1]; Aishwarya Hole[2]; Prathamesh Jadhav[3]; Himanshu Jadhav[4]; Tanishq Hogade[5]; Dr. Tushar Shelke[6]

[1]Assistant Professor, Department of Pharmaceutics, Genba Sopanrao Moze College of Pharmacy, Wagholi, Pune, Maharashtra. India
[2,3,4,5] Research Scholar, Genba Sopanrao Moze College of Pharmacy, Wagholi, Pune, Maharashtra. India
[6]Principal, Genba Sopanrao Moze College of Pharmacy, Wagholi, Pune, Maharashtra. India.

Publication Date: 2025/05/12

Abstract: In December 2019, a group of patients in Wuhan, China, developed an unexpected pneumonia. This led to the discovery of a new coronavirus, which the World Health Organization (WHO) called 2019 novel coronavirus (2019-nCoV) on January 7. After sequencing the novel virus's genome, scientists discovered that 86.9% of it is identical to the SARS-CoV genome. Later on, the nomenclature was modified to SARS-CoV-2, or Severe Acute Respiratory Syndrome Corona Virus 2. Nearly two hundred million cases have been confirmed and four million people have died globally in less than 18 months since the pandemic began. A lot of work has also gone into developing safe and efficient vaccines. There were 18 COVID-19 vaccines authorized for use in emergencies by at least one regulatory body by July 2021, 184 COVID-19 vaccine candidates in pre-clinical development, and 105 in clinical development. Protein-based, viral vector, nucleic acid, and entire virus live attenuated or inactivated vaccines are among them. By the middle of 2021, three billion doses of the COVID-19 vaccination had been distributed globally, primarily in wealthy nations. There is hope that the COVID-19 pandemic will cease if and only if all nations worldwide have optimal uptake and equal access to the vaccine. The development of vaccines to prevent the spread of the corona virus disease 2019 (COVID-19) has intensified as many nations continue to struggle with new infections brought on by the virus.

Keywords: *Covid-19, SARS-CoV-2, Vaccines, Safety, Technology, Global Impact.*

How to Cite: Dr. Ashwini Jadhav; Aishwarya Hole; Prathamesh Jadhav; Himanshu Jadhav; Tanishq Hogade; Dr. Tushar Shelke (2025) Covid-19 Vaccines: A Review on Technology, Safety and Global Impact. *International Journal of Innovative Science and Research Technology*, 10(4), 3213-3217. https://doi.org/10.38124/ijisrt/25apr1545

I. INTRODUCTION

A virus is the cause of COVID-19, also known as coronavirus disease 2019. The virus is known as SARS-CoV-2, or severe acute respiratory syndrome coronavirus 2. After a report of a number of "viral pneumonia" cases in Wuhan, People's Republic of China, WHO first became aware of this new virus on December 31, 2019. At the end of 2019, it began to spread 42, and in 2020, it turned into a pandemic. The infectious agent 7 that causes coronavirus illness (COVID-19) is the SARS-CoV-2 virus. The majority of virus-infected individuals had mild to severe respiratory infections that went away on their own and they healed without the need for any special medical care.SOlder people and those who were underlying with medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer were more prone to get a major disease. Understanding the illness made it simple to stop the virus's spread and transmission. During coughing, sneezing, speaking, and other activities, the virus was primarily spread by microscopic particles in the mouth or nose of an infected individual. In order to protect themselves during the pandemic, people wore a well fitted face mask, avoided close contact with others within one meter, and regularly washed their hands with an alcohol-based rub, such as sanitizer or disinfectant, after handling a foreign object continuously after touching a foreign object by alcohol-based rub i.e disinfectant or sanitizer [1].

➢ *Risk Factors*

The main risk factors for COVID-19 are:

- If someone you live with has COVID-19.
- If you spend time in places with poor air flow and a higher number of people when the virus is spreading.
- If you spend more than 30 minutes in close contact with someone who has COVID-19[1].

➢ *Structure of Corona Virus*

The spike (S), membrane (M), nucleocapsid (N), and tiny envelope (E) proteins are the four primary structural

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1545

proteins of SARS-CoV-2. Other auxiliary proteins are also present [2]. Located in the outer layer of the virus, the spike—also known as S glycoprotein—is a transmembrane protein with a molecular weight of roughly 150 kDa. By attracting the lower respiratory tract cells' angiotensin-converting enzyme 2 (ACE2), the S protein creates homotrimers that stick out of the viral surface and help the envelope virus cling to host cells. This glycoprotein is broken down by the host cell's Furin-like protease into two smaller components, S1 and S2. The composition of the receptor binding domain in Part S1 establishes the host virus's cellular tropism and range, while Part S2 encourages virus fusion in transmitting host cells [3]. Located in the endoplasmic reticulum-Golgi area, the nucleocapsid, also referred to as the N protein, is the structural element of Covid that is structurally connected to the nucleic acid content of the virus. Due to its RNA-binding function, the protein is involved in the viral genome, viral replication cycle, and host cell biology in response to viral infection. Furthermore, the increased phosphorylation of N protein may cause structural changes that heighten its affinity for viral DNA.[4].



Fig 1 Structure of Corona Virus

II. VACCINES

A vaccination is a biological agent created to stimulate the immune system so that it can recognize and combat specific germs or viruses. One of the most important scientific advances in recent history is the creation and widespread use of COVID-19 vaccinations. COVID-19 vaccines, which were first made available in late 2020, have significantly changed the course of the epidemic, saved millions of lives, and allowed civilizations to progressively return to normal. The technology underlying these vaccinations, their safety profiles, and their effects on public health around the world during the past few years are all thoroughly covered in this paper.

➢ *Types of Vaccines Platform –*

- *mRNA-Based Vaccines*

Vaccination technology has been revolutionized by the innovative messenger RNA (mRNA) vaccination platform. It distributes mRNA encapsulated in lipid nanoparticles (LNPs), as used in the Pfizer-BioNTech and Moderna vaccines. After entering cells, the mRNA instructs cells to create the SARS-CoV-2 spike protein by directly translating in the cytoplasm through ribosomes [5]. Without really causing illness, this protein then sets off an immunological reaction. The main benefit of mRNA technology is its capacity to be prepared quickly, which was essential during the pandemic emergency. Ionizable lipid nanoparticles are used to deliver nucleoside-modified mRNA containing the full-length spike protein of SARS-CoV-2 in the mRNA-1273 (Moderna) and BNT162b2 (Pfizer) vaccines. Compared to alternative vaccine platforms, the mRNA method is thought to be safer and possibly more effective [2].

- *DNA and Viral Vector Vaccines*

AstraZeneca's and other DNA-based vaccines employ double-stranded DNA, which is encased in viral vectors, in place of mRNA. DNA vaccines require an extra stage in the process because they must first enter the nucleus before transcription, whereas mRNA vaccines benefit from immediate cytoplasmic translation. One benefit of DNA vaccines over mRNA formulations is their increased durability. Long-term preservation and freeze-drying are made possible by the double-stranded DNA molecules' greater stability compared to viruses, proteins, and mRNA. Distribution logistics may be made easier by this stability, especially in areas with inadequate cold-chain infrastructure.

- *Plasmid DNA-Based Vaccines*

Plasmid DNA vaccines are an additional technical strategy that offers improved safety profiles by doing away with the necessity for live viruses. However, transfection efficacy is a problem for many vaccines, and they frequently need specific delivery methods. For instance, CELLECTRA, a portable electroporation tool used in Inovio's COVID-19 vaccine candidate (INO-4800), uses an electromagnetic pulse to pierce cell membranes and allow plasmid penetration. This strategy creates logistical challenges for mass immunization campaigns even if it makes use of proven technology to facilitate effective clinical trials.[5].

➢ *Viral Vaccine Components Include the Protein Subunit, which Contains Purified and Separated Viral Proteins.*

- **Virus-like Particles (VLP):** These particles have viral proteins that mimic the structure of the virus but lack genetic material. 3. Both DNA-based and RNA-based systems contain viral genetic material, such as mRNA, which provides the instructions for making viral proteins
- **Non-Replicated Viral Vector:** Consists of viral genetic material encased in a virus that is not capable of self-replication.
- **Replicating Viral Vector:** Consists of viral genetic material encased in a self-replicating, harmless virus.
- **Vaccines for entire viruses**
- **Inactivated:** Consists of viral copies that have been rendered inactive.
- **Live-Attenuated:** Consists of attenuated (weakened) copies of the virus.

III. VACCINE DEVELOPMENT AND MANUFACTURING PROCESS

The production of COVID-19 vaccines involves several intricate steps that transform laboratory research into safe,

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1545

effective immunizations. This process combines established scientific principles with cutting-edge technology.

➢ *Initial Development and Antigen Selection*

Rapid sequencing of the SARS-CoV-2 viral genome, which was promptly disseminated to researchers worldwide, marked the beginning of the creation of the COVID-19 vaccine. Because the spike protein gene is crucial for viral attachment to host cells, making it an excellent antigen for immune recognition, scientists used bioinformatics techniques to assess this sequence and chose it as the main vaccination candidate. The first step in the production of vaccines is the selection of suitable antigens, which necessitates a great deal of research to find ingredients that will successfully elicit an immune response [5].

For mRNA vaccines specifically, researchers optimized the spike protein genetic sequence based on years of previous coronavirus research. Understanding the viral genome also allowed for potential updates to address new viral strains that might emerge[4].

➢ *Clinical Trial Procedures for COVID-19 Vaccines*

- *Preclinical Testing*

Before human testing begins, vaccines undergo preclinical evaluation in laboratory settings and animal models. This phase assesses the vaccine's immunogenicity and potential side effects without human exposure. Only after demonstrating promising results in these preliminary studies do vaccines advance to human clinical trials[5].

- *The Three-Phase Clinical Trial Process[7]*

COVID-19 vaccines, like all vaccines, underwent a structured three-phase human clinical trial process:

✓ *Phase 1 Trials*

In this initial human testing phase, the vaccine is administered to a small group of volunteers to assess its safety, confirm that it generates an immune response, and determine appropriate dosing. These early trials typically involve young, healthy adult participants to minimize risk while establishing fundamental safety parameters.

✓ *Phase 2 Trials*

The vaccine is then administered to hundreds of volunteers to further evaluate safety and immune response. Participants in this phase share characteristics with the intended vaccine recipients. Multiple trials are often conducted during this phase to assess different age groups and vaccine formulations. A control group that does not receive the vaccine is typically included as a comparator to determine whether changes in the vaccinated group are attributable to the vaccine itself.

✓ *Phase 3 Trials*

Thousands of volunteers will receive the vaccine during the last pre-approval stage, and the results will be compared to those of a comparable group that received a comparator product or placebo. This extensive testing thoroughly assesses the vaccine's safety in a wide range of populations and conclusively proves its efficacy against the intended disease. To make sure results would hold true for a range of populations, phase 3 trials for COVID-19 vaccinations were frequently carried out in several nations and locations

Throughout Phases 2 and 3, "blinding" procedures are employed, meaning neither the volunteers nor the scientists conducting the study know which participants received the vaccine versus the comparator product. This approach prevents bias in safety and efficacy assessments. After trial completion and data finalization, both participants and researchers are informed of their group assignments.

➢ *Specific Example: Pfizer-BioNTech COVID-19 Vaccine Preparation*

The Pfizer-BioNTech vaccine provides a concrete example of the preparation process. The vaccine is supplied as a frozen suspension in multiple-dose vials that require thawing and dilution before administration. The preparation involves several precise steps:

- Thawing the vial either in a refrigerator (2-8°C) for up to three hours or at room temperature (up to 25°C) for 30 minutes.
- Gently inverting the vial 10 times before dilution to mix the contents.
- Diluting with 1.8 mL of sterile 0.9% Sodium Chloride Injection using aseptic technique.
- Equalizing pressure in the vial before removing the needle.
- Gently inverting the diluted vial 10 times to mix properly.
- Recording the date and time of dilution and storing appropriately[6].

This vaccine is administered intramuscularly as a series of two 0.3 mL doses given three weeks apart, with each vial containing five doses after proper dilution[6].

➢ *Regulatory Approval and Vaccine Distribution*

- **Regulatory Evaluation Process**: Following successful clinical trials, comprehensive data on the vaccine's safety, efficacy, and manufacturing processes are submitted to regulatory authorities such as the FDA in the United States. These bodies thoroughly review all aspects of the vaccine, analyzing results from preclinical and clinical studies to assess the risk-benefit profile before granting approval for public use. While COVID-19 vaccines were developed rapidly, they followed all essential steps to ensure safety and effectiveness. The development pathway included vaccine development, clinical trials, FDA authorization or approval, and development of recommendations through the Advisory Committee on Immunization Practices (ACIP) and CDC[5].
- **Post-Approval Monitoring**- After vaccines receive authorization for public distribution, monitoring systems continue to track safety and effectiveness. This ongoing surveillance is particularly important for COVID-19 vaccines given their rapid development timeline and novel technologies used in some formulations[9].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1545

IV. SAFETY PROFILE OF COVID-19 VACCINES

➢ *General Safety Considerations*

Throughout the course of their distribution, the safety profile of COVID-19 vaccinations has been thoroughly investigated and tracked. The safety profile of COVID-19 vaccines approved in the European Union is incredibly comforting, according to data collected from hundreds of millions of vaccinated people. Long-term safety data collected over more than two years of mass vaccination campaigns further supports this conclusion. A critical observation from safety monitoring is that most adverse effects typically manifest within two months of vaccination. This finding provides significant reassurance regarding the low likelihood of unexpected long-term complications emerging beyond this timeframe[6].

➢ *Safety in Special Populations*

- *Children and Adolescents*

Studies indicate that Despite being reactogenic, COVID-19 vaccinations are usually safe for kids. According to randomized controlled trials, this cohort has no elevated risk of significant adverse events, with a risk ratio of 0.83 (95% CI 0.21-3.33). According to real-world data, there are roughly 0.23–1.2 severe incidents for every 100,000 immunizations delivered.

The risk of solicited local reactions in children was approximately doubled after vaccination (RR 2.07 after first dose, 2.06 after second dose), while systemic reactions showed a more modest increase (RR 1.09 after first dose, 1.49 after second dose). Unsolicited adverse events were slightly more common in mRNA-vaccinated children compared to unvaccinated counterparts (RR 1.21). Regarding myocarditis, a specific concern with mRNA vaccines, the evidence remains uncertain with a risk ratio of 4.6 (0.1-156.1) and approximately 0.13-1.04 observed events per 100,000 administered vaccines[7].

- *Pregnant Women*

Evidence from multiple studies demonstrates that mRNA COVID-19 vaccines do not cause complications in pregnancy, either for expectant mothers or their babies. This finding is especially important given the increased risk that COVID-19 infection poses to pregnant women[6].

- *Monitoring and Rare Adverse Events*

Continuous safety surveillance has identified rare serious adverse events associated with COVID-19 vaccines, including anaphylaxis and myocarditis/pericarditis. However, the extremely low incidence of these events maintains a strongly favourable benefit-risk profile for the vaccines across populations.

The European Medicines Agency and regulatory authorities worldwide continue to closely monitor the safety of COVID-19 vaccines, ensuring that any emerging safety signals are promptly identified and addressed[6].

➢ *The Global Impact of the COVID-19 Vaccine*

- *Lives Saved and Disease Prevention*

Vaccines against COVID-19 have had a major impact on morbidity worldwide. Between the 8th of December 2020 and the 8th of December in 2021, vaccines are predicted to have averted 14.4 million lives worldwide, according to official reports of COVID-19 deaths. This estimate rises to 19.8 million lives saved when unreported COVID-19 deaths are taken into account using excess mortality statistics, which represents a 63% decrease in total deaths during the first year of immunization. These numbers prove how effective COVID-19 vaccinations have been in lessening the pandemic's effects. Mathematical models indicate that over 31.4 million COVID-19-related deaths would have happened throughout this time if immunization hadn't been implemented.[9].

- *Vaccine Effectiveness*

The effectiveness of updated COVID-19 vaccines has been demonstrated across various outcomes and populations. For adolescents and adults, vaccines showed 43% effectiveness against medically assisted COVID-19 (visits to the emergency room or urgent care centers), 44% effectiveness against hospitalization, and 23% effectiveness against death. In children, the vaccines demonstrated even stronger protection, with 80% effectiveness against medically-attended COVID-19. This higher effectiveness in younger populations may reflect their generally more robust immune responses to vaccination[8].

- *Equity in Global Vaccine Distribution[9]*

Despite the remarkable success of COVID-19 vaccines in preventing deaths globally, significant inequities in vaccine access have limited their potential impact. By the end of 2021, the COVID-19 Vaccines Global Access (COVAX) program aims to achieve 20% coverage in participating low-income countries, promoting equitable vaccine distribution. In the same way, by the end of 2021, the World Health Organization aimed for 40% coverage in every nation. However, a large number of low-income areas failed to meet these goals, underscoring ongoing difficulties in implementing equitable global health measures. According to analysis, better vaccine access might have saved over 41% of excess mortality (7.4 million deaths) in COVAX Advance Market Commitment nations alone. This obvious discrepancy emphasizes how critical it is to address systemic injustices in international health systems in order to better prepare for pandemics in the future.

- *Ongoing Monitoring and Future Directions*

the elaboration of sars- cov- 2 necessitates continued alert and adaption of vaccine strategies the who technical advisory group on covid- 19 vaccine composition label-co-vac continually monitors the inheritable and antigenic elaboration of sars- cov- 2 variants vulnerable responses to infection and vaccination and vaccine performance against circulating variants [10].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1545

V. CONCLUSION

The exploration now available suggests that the maturity of the population would profit from immunization with either the moderna or the pfizer biontech mrna vaccines anyhow of individual immunological status and contextual factors the success of the immunization program hinges on strong safety and efficacity substantiation as well as wide public acceptance and vaccination nevertheless vaccination hesitancy continues to be a significant issue in the us a large portion of this disinclination has redounded from a comparatively docked clinical trial process nevertheless cases and clinicians should flash back that these vaccinations like former vaccines passed the necessary due industriousness also the cdc is still keeping a careful eye on the effectiveness and safety of these vaccines. Additionally, before the vaccine was approved, the US federal government and industry partners had already built infrastructure for manufacturing the vaccine. Manufacturers of vaccines typically wait until phase 3 is finished before constructing such facilities. One Given the sharply polarized sociopolitical environment and the rapid vaccine development schedules for the COVID-19 vaccines in particular, vaccination trust may be further undermined and vaccination complacency may increase. The significance of universal immunization has been underscored by notable drops in new-onset COVID-19 infection rates in certain populations, such as nursing care patients, after vaccine distribution. To address persistent vaccine reluctance, comprehensive evidence-based initiatives aimed at behavior modification must be put into action. According to recent studies, a sizable portion of the public exhibits ambivalence and hesitancy around vaccines.These checks further suggest that vaccine hesitancy is more pronounced in populations who have been disproportionately affected by COVID- 19, including jobless individualities and those with lower educational situations, as well as among certain ethnical nonage groups including African Americans and Hispanic Americans. In order to address vaccine hesitancy and enhance COVID- 19 vaccine relinquishment,multi-tiered, evidencedbased approaches must be enforced. They include substantiation- grounded enterprise from behavioural, communication, perpetration, and social lores that can guide clinical programs at the organizational, relational, and individual situations to support public health enterprise and challenge COVID- 19 vaccine hesitancy. Important vaccine education platforms include; websites, TV, educational programs in academy, and vaccine education enterprise to serve areas with limited technological connection. Effective strategies to increase vaccine relinquishment include enforcing vaccination programs for the following seminaries and sodalities, woman- child programs, and penurious areas that have lower geographic access to vaccination centres.

REFERENCES

[1]. A.A. Rabaan, S.H. AlAhmed, R. Sah, R. Tiwari, M.I. Yatoo, S.K. Patel, M. Pathak, Y.S. Malik, K. Dhama , K.P. Singh, *et al. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic*

[2]. S. Jiang, C. Hillyer, L. Du Neutralizing antibodies against SARS-CoV-2 and other human Coronaviruses

[3]. A.R. Fehr, S. Perlman Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses

[4]. https://pmc.ncbi.nlm.nih.gov/articles/PMC8662109

[5]. https://pmc.ncbi.nlm.nih.gov/articles/PMC8540464/

[6]. https://www.indiascienceandtechnology.gov.in/covid-19-vaccine/vaccine-testing-and-approval-process

[7]. https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(23)00078-0/fulltext

[8]. https://www.cdc.gov/acip/grade/covid-19-2024-2025-6-months-and-older.html

[9]. https://pmc.ncbi.nlm.nih.gov/articles/PMC9225255/

[10]. https://www.who.int/news/item/25-03-2025-types-of-data-requested-to-inform-may-2025-covid-19-vaccine-antigen-composition-deliberations

[11]. D. Schoeman, B.C. Fielding Coronavirus envelope protein: current knowledge

[12]. Cordero DA: Rebuilding public trust: a clarified response to COVID–19 vaccine hesitancy predicament. J Public Health (Oxf) 2021. [Feb 5, online ahead of print].